Cathie Wood’s ARK sees major activity in CoreWeave and Personal Genome stock

Cathie Wood's ARK Investment Management reported significant trading activity on October 14, 2026. Notably, they acquired 188,665 shares of CoreWeave (CRWV) at $14,680,023, reinforcing their investment in the company's cloud infrastructure solutions. The same day, ARK sold 693,049 shares of Personal Genome Diagnostics (PSNL) for $10,984,826, continuing their trend of divesting from Personal Genome.

The trades also saw ARK purchasing 9,577 shares of Meta Platforms (META) for $7,302,462, reflecting their ongoing interest in major tech platforms. They offloaded 113,555 shares of 10X Genomics (TXG) for $8,152,113, aligning with their recent pattern of reducing positions in the genomics sector. Other transactions included the sale of 337,473 shares of Toast (TOST) for $10,424,540 and the purchase of 44,689 shares of Cerebras Systems (CBRS) for $6,662,683.

The list also features a sale of 31,432 shares of Palantir Technologies (PLTR) for $6,558,915, and a smaller purchase of 110,037 shares of Freenome (FRNM) for $1,390,867. ARK also acquired 500,457 shares of Kodiak AI (KDK) for $850,776 and bought 459 shares of Scribe Therapeutics (SCTX) for $8,776. These moves indicate ARK's strategic adjustments, prioritizing cloud infrastructure and key technology platforms while reducing exposure to certain e-commerce and genomics companies.